ArticleThe Eurasian journal of medicine2008
Prognostic importance of increased cyclooxygenase-2 levels in colorectal carcinomas: a 5-year single-institution study.
Article in The Eurasian journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCOX-2-selective inhibitors are used in the prevention and management of colorectal carcinogenesis. Our objective was to investigate if COX-2 levels have prognostic value in patients diagnosed with colorectal carcinoma. MATERIALS AND
methodsThis is a retrospective study of 112 patients diagnosed with colorectal carcinoma between 2000-2004 from the General Surgery Department at Haydarpasa Training Hospital, Gulhane Military Medical Academy. Patients were assessed according to age, gender, localization of the tumor, stage of the tumor, remote metastasis status, patient survival, COX-2 levels and grade of differentiation.
resultsCOX-2 levels significantly affect the duration of survival (P=0.026) and overall survival (P=0.013). The COX-2 significance value showed a tendency to change from negative to positive while a statistically meaningful decrease was observed in the survival value (r=-0.25; P=0.007) in groups related with the survival duration of cases (r=-0.24; P=0.01). The median survival was 36 (26.35-45.65) months. During the examination of survival statuses of cases, a statistically meaningful difference was determined between patients whom were alive and dead (P=0.01).
conclusionWe conclude that COX-2 levels are a negative predictor of survival.
Indexed as
Identifiers
25610014PMC4261324W2263770595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.